Shopping Cart

Your shopping cart is currently empty

Ellagic acid

Name: Ellagic acid
Brand: TargetMol
SKU: T0465
Price: 39 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T0465Cas No. 476-66-4

Alias Gallogen, Elagostasine

Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity.

Ellagic acid

Copy Product Info

😃Good

Purity: 99.75%

Catalog No. T0465Alias Gallogen, ElagostasineCas No. 476-66-4

Pack Size	Price	USA Warehouse	Global Warehouse
500 mg	$44	In Stock	In Stock
1 g	$63	In Stock	In Stock
5 g	$145	-	In Stock
1 mL x 10 mM (in DMSO)	$39	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.75%

Resource Download

COA

Product Introduction

Ellagic acid AI Summary

Ellagic acid is a bioactive compound with a broad range of inhibitory properties and therapeutic potential. It inhibits HIV-1 integrase with an IC50 value of 5100.0 nM, specifically targeting the 3''-preprocessing step. It also shows antimicrobial activity by inhibiting DNA gyrase supercoiling in Escherichia coli with IC50 values of 47.0 ug/mL and 3.3 ug/mL, as well as demonstrating antibacterial activity against various bacterial strains with MIC values ranging from 2.0 to 31.25 ug/mL. Additionally, Ellagic acid exhibits antiplasmodial effects against multiple strains of Plasmodium falciparum, with IC50 values from 105.0 nM to 330.0 nM, and demonstrates significant efficacy in vivo in mouse models. The compound is a potent inhibitor of various kinases, including CK2 with an IC50 of 40.0 nM, tyrosine protein kinase pp60 c-src with an IC50 of 300.0 nM, and protein kinase A with an IC50 of 600.0 nM. It also inhibits DNA polymerase eta and iota, with an IC50 of 62.0 nM for both enzymes, and has shown significant inhibition of RAT CK2, with a Ki of 20.0 nM. Furthermore, it affects multiple antioxidant enzymes and demonstrates strong antioxidant activities, such as DPPH radical scavenging (EC50 = 4.8 μg). The compound inhibits SphK1 with an IC50 of 740.0 nM, amyloid beta aggregation, various carbonic anhydrase isoforms, and multiple other enzymes and pathways, including IKKbeta, CK2alpha, and HIV1 RT. Ellagic acid also displays anti-inflammatory properties by reducing nitric oxide production in mouse RAW264.7 cells, with an IC50 value greater than 50000.0 nM. Additionally, Ellagic acid shows cytotoxic effects against cancer cell lines, such as a human cancer cell line in the NCI's anticancer drug screening program with a GI50 value of 10.0 nM, and demonstrates immunomodulatory activities. It also exhibits antiviral activity against SARS-CoV-2, EBOV, and MARV with respective IC50 values, and inhibits enzymes like maltase dehydrogenase, chymotrypsin, and cruzain. Ellagic acid is soluble in water at 9.7 ug/mL and has documented effects on glucose uptake in 3T3 L1 adipocytes, extending its potential applications as a therapeutic agent..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Ellagic acid (Gallogen), a thickened tetracyclic natural product, is a potent CK2 inhibitor (IC50=40 nM; Ki=20 nM) with ATP-competitive properties. Ellagic acid is an antioxidant and also possesses antiproliferative activity.
Targets&IC50	CK2:40 nM
In vitro	METHODS: Human pancreatic cancer cell lines PANC-1, AsPC-1 and MIA PaCA-2 were treated with Ellagic acid (10-1000 µM) for 24-72 h. Cell viability was measured by MTT assay. RESULTS: The proliferation of PANC-1 was inhibited by the addition of 10 µM Ellagic acid in a dose-dependent manner. The proliferation of AsPC-1 was inhibited by the addition of 100 µM Ellagic acid, while the proliferation of MIA PaCA-2 was inhibited only by the addition of 1000 µM Ellagic acid. [1] METHODS: Human lung cancer cells A549 were treated with Ellagic acid (5-20 µM) for 48 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: Ellagic acid treatment significantly down-regulated the phosphorylation of PI3K and Akt in a dose-dependent manner. [2]
In vivo	METHODS: To investigate the hepatoprotective effects on alcohol-induced liver disease (ALD), Ellagic acid (50-100 mg/kg suspended in 0.5% CMC-Na) was administered by gavage once daily for four weeks to ICR mice receiving 50% (v/v) alcohol orally daily. RESULTS: Ellagic acid attenuated oxidative stress, inflammatory response, steatosis and gut microbiota dysbiosis in ALD mice. [3]
Synonyms	Gallogen, Elagostasine

Chemical Properties

Molecular Weight	302.19
Formula	C₁₄H₆O₈
Cas No.	476-66-4
Smiles	OC1=CC2=C3C(OC(=O)C4=CC(O)=C(O)C(OC2=O)=C34)=C1O
Relative Density.	1.667 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 3.03 mg/mL (10.03 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Saline: 0.15 mg/mL (0.5 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	3.3092 mL	16.5459 mL	33.0918 mL	165.4588 mL
5 mM	0.6618 mL	3.3092 mL	6.6184 mL	33.0918 mL
10 mM	0.3309 mL	1.6546 mL	3.3092 mL	16.5459 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc